Molina's 92.7% Medicaid MLR and a Trough Call the Acuity Math Hasn't Confirmed

Molina Healthcare's Medicaid medical cost ratio ran 92.7% in the second quarter of 2026, up from 91.3% a year earlier, while Medicare came in at 90.7% and Marketplace at 88.9%, pushing the consolidated ratio to 92.2% (Molina Healthcare, July 22, 2026). The company raised full-year adjusted earnings guidance anyway, to at least $5.25 per diluted share, and CEO Joseph Zubretsky called 2026 the trough year for Medicaid margins.

Adjusted earnings per share of $1.51 beat the $1.40 consensus estimate by eight cents, on $10.9 billion of total revenue and $10.2 billion of premium revenue, itself down 6% year over year as membership contracted (Molina Healthcare Q2 2026 earnings release, July 22, 2026). Six months into the year, adjusted EPS of $3.86 trails the $11.56 booked in the first half of 2025 by a wide margin, a reminder that "trough" in this context means a genuinely compressed earnings base, not a modest dip. The stock's reaction was muted rather than celebratory: several outlets flagged that in-line revenue paired with only a partial guidance recovery is not the same signal as a clean beat-and-raise, and the segment detail explains why.

The Segment Split: Medicaid Worse, Medicare Better, Marketplace the Wild Card

Molina's three reporting segments moved in three different directions this quarter, which is itself the more useful story than the consolidated number. Medicaid's MCR deteriorated 140 basis points year over year to 92.7%, Medicare improved 70 basis points to 90.7%, and Marketplace worsened by 350 basis points to 88.9% from 85.4% a year earlier (Molina Healthcare, July 22, 2026). Management characterized the Medicaid print as "in line with the Company's expectation," the Medicare print as "better than the Company's expectation," and the Marketplace print as "higher than the Company's expectations" (Molina Healthcare Q2 2026 earnings release, July 22, 2026).

Segment	Q2 2026 MCR	Q2 2025 MCR	Change	Membership (June 30, 2026)
Medicaid	92.7%	91.3%	+140 bps	4.418 million
Medicare	90.7%	90.0%	+70 bps	224,000
Marketplace	88.9%	85.4%	+350 bps	283,000
Consolidated	92.2%	90.4%	+180 bps	4.926 million

A Medicaid MCR that is "in line" at 92.7%, worse than a year ago, sounds like an odd input for a trough call, and the mechanism is entirely rate timing. Medicaid capitation rates are set once or twice a year by state Medicaid agencies and certified under 42 CFR 438.4's actuarial soundness framework using a historical base period, which means the rate a state pays in mid-2026 was built on cost data from well before the redetermination-driven acuity shifts and elevated behavioral health and specialty pharmacy utilization that have been running through the managed care sector since 2024. When Zubretsky says the rate-to-trend gap "appears to have stabilized," he is describing the two lines converging, not the ratio itself improving yet. "The imbalance between Medicaid rates and medical cost trend appears to have stabilized and is well positioned to be corrected with future rate increases. This reinforces our belief that 2026 is the trough year for Medicaid pretax margins" (Joseph Zubretsky, Molina Healthcare Q2 2026 earnings release, July 22, 2026). A stabilized gap that state rate-setters are now positioned to close is a materially weaker claim than a gap that has already closed, and the distinction matters more than the headline "trough" framing suggests.

Marketplace's 350-Basis-Point Slide: Risk Adjustment, Program Integrity, and Acuity

The segment that actually surprised Molina's own model was Marketplace, not Medicaid. The 88.9% MCR reflected "prior year risk adjustment and program integrity initiatives and the impact of current year unfavorable member acuity mix" (Molina Healthcare Q2 2026 earnings release, July 22, 2026), three distinct drags stacked in one disclosure. The prior-year risk adjustment component means Molina's 2025 accident-year ACA risk-transfer receivable came in lower than booked, a true-up that flows through the current period's MCR even though the underlying claims experience is a year old. Program integrity initiatives, CMS's tightened verification of ACA subsidy eligibility and enrollment following the well-documented 2025 to 2026 wave of improper-enrollment scrutiny, is removing marginal enrollees from exchange rolls nationally, and the members most likely to be caught by stricter verification tend to be lower-utilizers who signed up opportunistically rather than the sicker members who fought to stay enrolled. That selection dynamic is the same mechanism driving the "current year unfavorable member acuity mix" Molina cited separately: a shrinking, more adversely selected Marketplace book raises the average cost per remaining member even if nothing about underlying medical trend has changed. Molina's own guidance bridge makes the scale of the surprise explicit: a $1.50 per-share increase from better-than-expected Medicare performance is offset almost exactly by a $1.50 per-share decrease in Marketplace, a dollar-for-dollar swap embedded inside an otherwise unchanged full-year outlook (Molina Healthcare, July 22, 2026).

Medicare's 90.7%: 2026 Repricing Doing Its Job

Medicare is the one segment where Molina's own pricing decisions, rather than external policy timing, get the credit. The 70-basis-point improvement to 90.7% reflects "lower medical cost trend and pricing implemented for 2026" (Molina Healthcare Q2 2026 earnings release, July 22, 2026), consistent with the broader Medicare Advantage repricing cycle that has been running across the sector since the 2024 to 2025 cost shock forced most national carriers to bid materially higher for the 2026 plan year. That repricing is not free, however. Full-year guidance embeds a $1.00 per-share loss tied to the performance of Molina's traditional MAPD product, which the company has already announced it will exit for 2027, alongside a separate $1.50 per-share loss from the new Florida Medicaid contract that begins in the fourth quarter of 2026 (Molina Healthcare Q2 2026 earnings release, July 22, 2026). Both figures are real components of the "at least $5.25" guidance, and both are costs concentrated in exactly the two areas, a product line being wound down and a new state contract still ramping, where near-term losses are most likely to be underestimated at the point of certification.

The Redetermination Math That Complicates the Trough Call

The mechanical risk to Zubretsky's trough thesis is not medical trend accelerating further; it is the composition of Molina's own 4.418 million Medicaid members shifting in a direction the certified capitation rates did not anticipate. Every state's six-month or annual redetermination cycle removes members from Medicaid rolls, and the removal is not random. KFF's Medicaid Enrollment and Unwinding Tracker found that 69% of disenrollments during the 2023 to 2024 unwinding were procedural, meaning the member lost coverage over paperwork rather than a genuine finding of ineligibility, and procedural disenrollment falls disproportionately on younger, healthier enrollees who are least motivated to complete renewal paperwork for coverage they rarely use (KFF Medicaid Enrollment and Unwinding Tracker). The mirror image of that pattern is what should worry a Medicaid MCO actuary reading a 92.7% MCR and calling it stable: as the healthier share of the book churns off faster than the sicker share, the members who remain enrolled skew progressively costlier, and that morbidity drift shows up in claims experience well before the next rate-setting cycle has a chance to reflect it in a new capitation rate.

This is precisely the dynamic this site has flagged as the structural risk sitting underneath every Medicaid MCO's 2026 rate assumptions: a rate certified under 42 CFR 438.4 for a twelve-month period embeds a population morbidity assumption as of the certification date, and mid-period adjustments are capped at 1% of the certified rate before a full re-certification is required, a process that adds months of regulatory lag (actuary.info's analysis of OBBBA-driven mid-cycle capitation repricing). The One Big Beautiful Bill Act's move to six-month redeterminations for expansion adults, beginning December 31, 2026, doubles the frequency of exactly the selection effect that produced the 69% procedural-disenrollment figure, compressing the reentry window that previously let procedurally disenrolled members rejoin before the adverse-selection effect compounded (actuary.info's six-month redetermination analysis). Molina's Medicaid membership of 4.418 million as of June 30, 2026 is the base against which that dynamic will play out over the next several quarters, and a 92.7% MCR measured before the accelerated cycle begins is not necessarily a reliable read on where the ratio settles once it does. Calling 2026 a trough assumes the rate-to-trend gap closes faster than the acuity mix worsens; the redetermination timeline argues the two forces are set to collide in the same window, not resolve sequentially.

Three Managed-Care Insurers, One "Trough Year" Framing

Molina is not alone in reaching for trough language this earnings season, and the company it most resembles in that respect, Elevance Health, arrived at a worse number from a different mechanism. Elevance's Q2 2026 benefit expense ratio rose to 89.7% from 88.9% a year earlier, driven by elevated Medicaid and Medicare Advantage cost trend that offset improved Individual ACA performance, and CFO Mark Kaye described 2026 as "the expected low point before profitability improves" (Mark Kaye, Elevance Health Q2 2026 earnings call, July 15, 2026). Elevance's full-year Medicaid segment operating margin is expected to land at negative 1.75%, an outright loss on the book, and CEO Gail Boudreaux confirmed the company will exit additional Medicaid markets over the next 12 to 18 months where it sees "no path to sustainable performance" (Gail Boudreaux, Elevance Health Q2 2026 earnings call, July 15, 2026). UnitedHealth moved the opposite direction entirely: its medical benefit ratio fell 270 basis points to 86.7% in the same quarter, helped by Medicare Advantage repricing and by shedding 380,000 Medicaid members through a planned Louisiana exit (UnitedHealth Group, July 16, 2026).

Read together, the three prints describe not one trough but two different paths to the word. UnitedHealth's improvement came substantially from walking away from underpriced Medicaid exposure rather than from the remaining book getting cheaper to serve, the same exit-driven mechanism Elevance says it will lean on next. Molina, by contrast, has not announced comparable Medicaid market exits and is calling its trough while still carrying the full 4.418 million members whose acuity mix is the open variable. A trough claim built on shrinking out of the worst-performing geography is a different, more defensible claim than a trough claim built on holding share and waiting for state rate-setters to catch up, and Molina's guidance raise rests on the second, harder-to-verify version.

What the Guidance Raise Signals to 2027 Rate Negotiators

The timing carries a real cost for Molina's own advocacy position. State Medicaid agencies are in the middle of setting 2027 capitation rates using the CMS 2026-2027 Medicaid Managed Care Rate Development Guide framework, and an MCO's own public guidance is not invisible to state actuaries and legislative budget staff running that process (CMS, February 2026). A national Medicaid MCO raising full-year earnings guidance and calling the current margin environment a trough about to improve is a data point state rate reviewers can use to argue that the existing rate-to-trend gap is closing on its own, without a rate action as large as the MCO's own actuaries might otherwise request. That tension is not hypothetical: MCOs and states negotiate certified rates adversarially within the actuarial soundness framework, and a guidance raise timed just as 2027 rate development gets underway hands state negotiators exactly the argument an MCO's own rate-adequacy case would prefer they not have.

The more durable actuarial signal sits underneath the guidance number, not in it. A trough call resting on a stabilizing rate-to-trend gap, rather than one already closed, is contingent on state legislatures and Medicaid agencies approving the rate increases Zubretsky's language assumes are coming, at the same moment those states are absorbing the fiscal effects of OBBBA's roughly $840 billion in ten-year Medicaid spending reductions and its own six-month redetermination mandate (Congressional Budget Office, 2025). Certifying actuaries at Molina, Elevance, and every other Medicaid MCO heading into the 2027 rating period are effectively betting that state rate-setters move fast enough to offset a acuity mix that is set to deteriorate on a faster clock than any annual base period was built to anticipate. The Q2 2026 MCR by itself does not resolve that bet either way; it is simply the most recent data point in a mechanism that will not fully reveal its direction until the first full quarter of accelerated redeterminations runs through claims experience in 2027.